Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago
🌐 বাংলায় দেখুন

Indications

Psoriasis

Deucrava is used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It isn't recommended for use together with other potent immunosuppressants.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2), which belongs to the Janus kinase (JAK) family. It binds to the regulatory domain of TYK2 and stabilizes an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. The result is allosteric inhibition of receptor-mediated activation of TYK2, and of its downstream activation of Signal Transducers and Activators of Transcription (STATs), as shown in cell-based assays.

JAK kinases, TYK2 included, work as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to mediate multiple cytokine pathways, and it also pairs with JAK2 to transmit signals, again as shown in cell-based assays. How inhibiting the TYK2 enzyme leads to a therapeutic effect in adults with moderate-to-severe plaque psoriasis is not currently known.

Pregnancy & Breastfeeding

Case reports on Deucravacitinib use in pregnancy don't give enough information to judge whether the medicine carries a risk of major birth defects, miscarriage, or other bad outcomes for the mother or the baby. In animal reproductive studies, no effect on embryo-fetal development was seen.

Nothing is known about whether Deucravacitinib passes into human milk, what it does to a breastfed infant, or whether it changes milk production. So the benefits of breastfeeding for the baby's development and health should be weighed together with the mother's clinical need for Deucravacitinib, and with any possible adverse effects of the medicine on the breastfed infant.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Recommended Evaluations and Immunizations Prior to Treatment Initiation Check patients for active and latent tuberculosis (TB) infection before starting Deucravacitinib. If the result is positive, begin TB treatment first, then start Deucravacitinib. Recommended Dosage The recommended dosage of Deucravacitinib is 6 mg taken orally once daily, with or without food. Don't crush, cut or chew the tablets. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use No overall differences in effectiveness have been observed between patients aged 65 years and older and younger adult patients. Recommended Dosage in Patients with Hepatic Impairment Deucravacitinib is not recommended in patients with severe hepatic impairment (Child-Pugh C). Patients with mild to moderate hepatic impairment need no dosage adjustment. Renal Impairment No dose adjustment is recommended in patients with mild, moderate or severe renal impairment, or in patients with end stage renal disease (ESRD) on dialysis.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.